MZMin Zou

Min Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Zou has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Li

    Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China

    8 shared publications
  • Xun Feng

    Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China

    7 shared publications
  • Mintong Wei

    Department of Dermatology and Venereology & Rare Diseases Center, West China Hospital Sichuan University Chengdu China

    6 shared publications
  • Jishu Li

    Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China

    5 shared publications
  • Kun Zhan

    Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China

    4 shared publications
  • Luyuan Li

    The First School of Clinical Medicine Southern Medical University Guangzhou Guangdong China

    4 shared publications

Latest Publications

  • Open Access

    Bullous Pemphigoid: A Focused Review on Antigen Epitopes

    by Jishu Li, Xun Feng, Min Zou, Mintong Wei, Wei Li

    Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease, characterized by autoantibodies against BP180 and BP230. Although the NC16A domain of BP180 is the immunodominant epitope, increasing evidence indicates that non‐NC16A epitopes also contribute to the clinical heterogeneity of BP. This review summarizes the immunological characteristics and clinical significance of BP180 and BP230 epitopes, and discusses their associations with disease phenotypes, treatment responses, and prognosis. We also outline the pathogenesis and animal models of BP, and highlight the rarity of validated models for non‐NC16A epitopes and their limited mechanistic scope. Emerging targeted therapies are critically reviewed in relation to current knowledge of epitope‐specific immune responses. Although epitope profiling may eventually contribute to disease stratification and biomarker development, current evidence is insufficient to support routine epitope‐guided therapeutic decision‐making. Despite current progress, challenges remain in clarifying the pathogenicity of non‐NC16A epitopes and establishing standardized detection. Future research should focus on epitope–phenotype correlations and large‐cohort studies to promote the development of precision therapy for BP.

  • Dupilumab for pruritus associated with dystrophic epidermolysis bullosa: A systematic review

    by Kun Zhan, Min Zou, Yusha Chen, Kaixin Lei, Keqin Xu, Luyuan Li, Guo Peng, Yue Xiao, Jishu Li, Xun Feng, et al.


  • Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles

    by Min Zou, Xun Feng, Jishu Li, Tong Li, Yiyi Wang, Luyuan Li, Guo Peng, Mintong Wei, Yi Teng, Kun Zhan, et al.

    Bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI‐BP) is a rare immune‐related adverse event that affects patient prognosis and management; however, comparative data between ICI‐BP and non‐ICI BP, especially the dynamic changes of antibodies remain scarce. Therefore, we conducted this study to compare clinical presentation, immunological profile, treatment, management, and outcomes of ICI‐BP versus non‐ICI BP. This was a retrospective, single‐centre cohort study of consecutive patients between 2019 and 2025. Patients with ICI‐BP (Group A) were compared with Group B (BP with concurrent malignancy but no ICI exposure) and Group C (classic BP). There were 34, 10, and 68 patients enrolled in Groups A, B, and C, respectively (median follow‐up 24.5 months, IQR 10.8–50.0). ICI‐BP presented at a younger age (median, 59.0 years; IQR, 53.3–69.5; p < 0.001) and showed a marked male predominance (88.2%; p = 0.003). A transient, albeit non‐significant, rise in anti‐BP180 reactivity was observed during the first 2 months in ICI‐BP. Systemic glucocorticoids were required more frequently in ICI‐BP, and IL‐4 inhibitors demonstrated superior potency in accelerating BP180 antibody decline compared to non‐systematic therapy. Tumour response rates were similar between Groups A and B, as was mortality across the three groups. In conclusion, ICI‐BP differs from non‐ICI BP in clinical and immunological features and more often necessitates systemic glucocorticoid therapy, while IL‐4 inhibitors potentially expedite the reduction of anti‐BP180 antibodies in ICI‐BP patients.


  • Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review

    by Min Zou, Xun Feng, Kun Zhan, Hongli Wang, Jiyun Pang, Jishu Li, Guo Peng, Mintong Wei, Luyuan Li, Yue Xiao, et al.

    Background: Autoimmune bullous diseases (AIBDs) constitute a rare yet potentially life‐threatening subset of immune‐related adverse events induced by immune checkpoint inhibitors (ICIs). However, the characteristics of ICI‐induced AIBDs (ICI‐AIBDs) and the factors influencing patient survival remain incompletely characterized. Therefore, we aimed to synthesize the available information on ICI‐AIBD patients and sought to explore factors potentially influencing the survival outcome of this population. Methods: A systematic search of 5 databases was conducted. Cox regression analysis was used to identify potential factors affecting patient survival outcomes. Results: Finally, a total of 188 studies with 319 participants were analyzed. The spectrum of AIBDs comprised bullous pemphigoid ( n = 254, 79.6%), lichen planus pemphigoides ( n = 34, 10.7%), mucous membrane pemphigoid ( n = 11, 3.4%), pemphigus group ( n = 7, 2.2%), linear IgA bullous dermatosis ( n = 5, 1.6%), primarily induced by programmed cell death protein 1 inhibitors. In the exploratory analysis, female (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.10–5.02; p = 0.020) and pemphigus group (HR, 7.09; 95% CI, 1.87–26.96; p = 0.003) were potentially associated with higher mortality, whereas topical glucocorticoid therapy was potentially protective (HR, 0.44; 95% CI, 0.21–0.93; p = 0.025). Conclusions: In conclusion, we delineate the full clinical spectrum of ICI‐AIBDs, tentatively exploring factors potentially affecting patients' survival, which provides insights for individualized therapy and may inform future clinical practice.


  • Dapagliflozin‐Associated Bullous Pemphigoid

    by Xun Feng, Mintong Wei, Jishu Li, Qingfeng Liu, Min Zou, Luyuan Li, Takashi Hashimoto, Wei Li


  • Autoimmune Bullous Disease Combined With Acquired Hemophilia A: A Systematic Review and Case Analysis

    by Min Zou, Kun Zhan, Xun Feng, Jishu Li, Mintong Wei, Xiwen Zhang, Hongxiang Hu, Xingli Zhou, Mi Wang, Xuemei Liu, et al.

    Autoimmune bullous diseases (AIBDs) are rare, chronic conditions characterized by blisters and erosions on the skin and mucous membranes. Acquired hemophilia A (AHA) is a rare bleeding disorder in which autoantibodies target coagulation factor VIII, often associated with other autoimmune diseases. However, the simultaneous occurrence of AIBD and AHA is rare, with limited understanding of their combined impacts. We aimed to synthesize the available evidence and provide insights into clinical manifestations, treatment strategies, and survival outcomes of such patients. We searched for relevant literature in four databases: PubMed, Web of Science, EMBASE, and Scopus, and combined patient information from our hospital to provide a comprehensive analysis. A total of 80 patients were included. Through log‐rank tests, older age (p = 0.03) and bullous pemphigoid (BP) (p = 0.047) were associated with shorter survival time. In the multivariate Cox proportional hazards regression model, mortality was only associated with older age (HR: 1.13, p = 0.02). Patients presenting both AIBD and AHA exhibit intricate clinical presentations and are at risk of severe, potentially fatal outcomes. Clinicians should remain vigilant regarding bleeding in AIBD patients, particularly those with BP and those in the geriatric population.